If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEMATOLOGY<br /> ISSN 2053-6631 Vol 4.1 • July 2016 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EHA 2016<br /> Copenhagen, Denmark<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 5<br /> CONGRESS REVIEW........................................................................................................................................ 10<br /> • Review of the 21st European Hematology Association (EHA) Annual Congress<br /> 2016, held in Copenhagen, Denmark, 9th–12th June 2016<br /> INTERVIEWS WITH EMJ HEMATOLOGY EDITORIAL BOARD............................................................... 22<br /> SYMPOSIUM REVIEWS<br /> • BIOSIMILARS: SHAPING THE FUTURE IN HAEMATOLOGY............................................................. 30<br /> <a title="EMJ Hematology 4.1 2016 page 1" href="http://viewer.zmags.com/publication/596c0327?page=1"> HEMATOLOGY ISSN 2053-6631 </a> <a title="EMJ Hematology 4.1 2016 page 2" href="http://viewer.zmags.com/publication/596c0327?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Hematology 4.1 2016 page 3" href="http://viewer.zmags.com/publication/596c0327?page=3"> HEMATOLOGY • BRIDGING TO TRANSPLANT IN DIFFUS</a> <a title="EMJ Hematology 4.1 2016 page 4" href="http://viewer.zmags.com/publication/596c0327?page=4"> Gaucher disease? He's relying on your diagnosis t</a> <a title="EMJ Hematology 4.1 2016 page 5" href="http://viewer.zmags.com/publication/596c0327?page=5"> Editorial Board Editor-in-Chief: Prof Emili Mo</a> <a title="EMJ Hematology 4.1 2016 page 6" href="http://viewer.zmags.com/publication/596c0327?page=6"> SUBSCRIBE TOTHEEMJ NEWSLETTER NwEwwW.newSs.eLmjEr</a> <a title="EMJ Hematology 4.1 2016 page 7" href="http://viewer.zmags.com/publication/596c0327?page=7"> Welcome Welcome to this edition of our journal</a> <a title="EMJ Hematology 4.1 2016 page 8" href="http://viewer.zmags.com/publication/596c0327?page=8"> Illuminating an underlying cause of haemolytic an</a> <a title="EMJ Hematology 4.1 2016 page 9" href="http://viewer.zmags.com/publication/596c0327?page=9"> Foreword </a> <a title="EMJ Hematology 4.1 2016 page 10" href="http://viewer.zmags.com/publication/596c0327?page=10"> 10 HEMATOLOGY • July 2016 </a> <a title="EMJ Hematology 4.1 2016 page 11" href="http://viewer.zmags.com/publication/596c0327?page=11"> HEMATOLOGY • July 2016 </a> <a title="EMJ Hematology 4.1 2016 page 12" href="http://viewer.zmags.com/publication/596c0327?page=12"> 12 HEMATOLOGY • July 2016 </a> <a title="EMJ Hematology 4.1 2016 page 13" href="http://viewer.zmags.com/publication/596c0327?page=13"> Congress Highlights GSGN-CD33A Antib</a> <a title="EMJ Hematology 4.1 2016 page 14" href="http://viewer.zmags.com/publication/596c0327?page=14"> Results of Ongoing Gene Therapy Study for Haemoph</a> <a title="EMJ Hematology 4.1 2016 page 15" href="http://viewer.zmags.com/publication/596c0327?page=15"> in Copenhagen, Denmark, according to a EHA press </a> <a title="EMJ Hematology 4.1 2016 page 16" href="http://viewer.zmags.com/publication/596c0327?page=16"> The risk of blood cancer is a particular concern </a> <a title="EMJ Hematology 4.1 2016 page 17" href="http://viewer.zmags.com/publication/596c0327?page=17"> Potential Alternative for Relapsed and Refractory</a> <a title="EMJ Hematology 4.1 2016 page 18" href="http://viewer.zmags.com/publication/596c0327?page=18"> however, offers a new treatment alternative for </a> <a title="EMJ Hematology 4.1 2016 page 19" href="http://viewer.zmags.com/publication/596c0327?page=19"> TKIs have significantly improved the survival rate</a> <a title="EMJ Hematology 4.1 2016 page 20" href="http://viewer.zmags.com/publication/596c0327?page=20"> Despite this, cHL should still be a high priority</a> <a title="EMJ Hematology 4.1 2016 page 21" href="http://viewer.zmags.com/publication/596c0327?page=21"> With promising survival outcomes and a relatively</a> <a title="EMJ Hematology 4.1 2016 page 22" href="http://viewer.zmags.com/publication/596c0327?page=22"> Klaus-Michael Debatin Chairman, Department of Pa</a> <a title="EMJ Hematology 4.1 2016 page 23" href="http://viewer.zmags.com/publication/596c0327?page=23"> about the long-term sequelae of our patient</a> <a title="EMJ Hematology 4.1 2016 page 24" href="http://viewer.zmags.com/publication/596c0327?page=24"> our understanding of the nature of diseases</a> <a title="EMJ Hematology 4.1 2016 page 25" href="http://viewer.zmags.com/publication/596c0327?page=25"> Ruben Mesa Professor of Medicine, Consultant Hem</a> <a title="EMJ Hematology 4.1 2016 page 26" href="http://viewer.zmags.com/publication/596c0327?page=26"> Q: What experimental treatments are you currently</a> <a title="EMJ Hematology 4.1 2016 page 27" href="http://viewer.zmags.com/publication/596c0327?page=27"> Q: What has been the proudest achievement of your</a> <a title="EMJ Hematology 4.1 2016 page 28" href="http://viewer.zmags.com/publication/596c0327?page=28"> to treating thalassaemia, introducing the id</a> <a title="EMJ Hematology 4.1 2016 page 29" href="http://viewer.zmags.com/publication/596c0327?page=29"> Exclusive Videos on Hematology (Clic</a> <a title="EMJ Hematology 4.1 2016 page 30" href="http://viewer.zmags.com/publication/596c0327?page=30"> BIOSIMILARS: SHAPING THE FUTURE IN HAEMATOLOGY </a> <a title="EMJ Hematology 4.1 2016 page 31" href="http://viewer.zmags.com/publication/596c0327?page=31"> Increasing demand for healthcare • Ageing</a> <a title="EMJ Hematology 4.1 2016 page 32" href="http://viewer.zmags.com/publication/596c0327?page=32"> assess whether there are any clinically significan</a> <a title="EMJ Hematology 4.1 2016 page 33" href="http://viewer.zmags.com/publication/596c0327?page=33"> The Science of Biosimilars: From Quality to Ex</a> <a title="EMJ Hematology 4.1 2016 page 34" href="http://viewer.zmags.com/publication/596c0327?page=34"> and clinical data between the biosimilar and the </a> <a title="EMJ Hematology 4.1 2016 page 35" href="http://viewer.zmags.com/publication/596c0327?page=35"> Reference Bio</a> <a title="EMJ Hematology 4.1 2016 page 36" href="http://viewer.zmags.com/publication/596c0327?page=36"> REFERENCES 1. Baer II WH et al. Barriers to the </a> <a title="EMJ Hematology 4.1 2016 page 37" href="http://viewer.zmags.com/publication/596c0327?page=37"> biopharmaceuticals. Nat Biotechnol. 2011; 29(4):3</a> <a title="EMJ Hematology 4.1 2016 page 38" href="http://viewer.zmags.com/publication/596c0327?page=38"> ADVANCES IN THE TREATMENT OF NON-HODGKIN’S </a> <a title="EMJ Hematology 4.1 2016 page 39" href="http://viewer.zmags.com/publication/596c0327?page=39"> of disease progression, in whom the benefits</a> <a title="EMJ Hematology 4.1 2016 page 40" href="http://viewer.zmags.com/publication/596c0327?page=40"> PI3K inhibitors • Idelalisib Immune checkpoin</a> <a title="EMJ Hematology 4.1 2016 page 41" href="http://viewer.zmags.com/publication/596c0327?page=41"> treatments, and is supported by clinical da</a> <a title="EMJ Hematology 4.1 2016 page 42" href="http://viewer.zmags.com/publication/596c0327?page=42"> Although patients with GCB typically respond</a> <a title="EMJ Hematology 4.1 2016 page 43" href="http://viewer.zmags.com/publication/596c0327?page=43"> partial response after salvage therapy achie</a> <a title="EMJ Hematology 4.1 2016 page 44" href="http://viewer.zmags.com/publication/596c0327?page=44"> CC-122 Immunomodulatory effects </a> <a title="EMJ Hematology 4.1 2016 page 45" href="http://viewer.zmags.com/publication/596c0327?page=45"> REFERENCES 1. Solal-Céligny P et al. F</a> <a title="EMJ Hematology 4.1 2016 page 46" href="http://viewer.zmags.com/publication/596c0327?page=46"> With Newly Diagnosed Non-Germinal Center B-Cel</a> <a title="EMJ Hematology 4.1 2016 page 47" href="http://viewer.zmags.com/publication/596c0327?page=47"> NEW INSIGHTS IN BONE MARROW FAILURE This sat</a> <a title="EMJ Hematology 4.1 2016 page 48" href="http://viewer.zmags.com/publication/596c0327?page=48"> AA/PNH LGL </a> <a title="EMJ Hematology 4.1 2016 page 49" href="http://viewer.zmags.com/publication/596c0327?page=49"> leading to apoptosis and BMF; a significant </a> <a title="EMJ Hematology 4.1 2016 page 50" href="http://viewer.zmags.com/publication/596c0327?page=50"> specific marker and the diagnosis is mainly </a> <a title="EMJ Hematology 4.1 2016 page 51" href="http://viewer.zmags.com/publication/596c0327?page=51"> Paroxysmal nocturnal haemoglobinuria Haemolytic </a> <a title="EMJ Hematology 4.1 2016 page 52" href="http://viewer.zmags.com/publication/596c0327?page=52"> bacterial infections with antibiotics, hydration </a> <a title="EMJ Hematology 4.1 2016 page 53" href="http://viewer.zmags.com/publication/596c0327?page=53"> Sci U S A. 2006;103(39):14483-8. 18. Townsley DM </a> <a title="EMJ Hematology 4.1 2016 page 54" href="http://viewer.zmags.com/publication/596c0327?page=54"> Hämoglobinurie (PNH). 2015. Available view/</a> <a title="EMJ Hematology 4.1 2016 page 55" href="http://viewer.zmags.com/publication/596c0327?page=55"> NAVIGATING THE CHANGING MULTIPLE MYELOMA TREAT</a> <a title="EMJ Hematology 4.1 2016 page 56" href="http://viewer.zmags.com/publication/596c0327?page=56"> Exploring Recent Developments in Multiple Myel</a> <a title="EMJ Hematology 4.1 2016 page 57" href="http://viewer.zmags.com/publication/596c0327?page=57"> (IGH) translocations and hyperdiploidy. Transitio</a> <a title="EMJ Hematology 4.1 2016 page 58" href="http://viewer.zmags.com/publication/596c0327?page=58"> Table 1a: Phase III trials in relapsed/refractory</a> <a title="EMJ Hematology 4.1 2016 page 59" href="http://viewer.zmags.com/publication/596c0327?page=59"> Table 1b: Phase III trials in relapsed/refractory</a> <a title="EMJ Hematology 4.1 2016 page 60" href="http://viewer.zmags.com/publication/596c0327?page=60"> therapies. Furthermore, a meta-analysis of triple</a> <a title="EMJ Hematology 4.1 2016 page 61" href="http://viewer.zmags.com/publication/596c0327?page=61"> treatment should continue until progressi</a> <a title="EMJ Hematology 4.1 2016 page 62" href="http://viewer.zmags.com/publication/596c0327?page=62"> immunomodulatory drugs, histone deacetylase</a> <a title="EMJ Hematology 4.1 2016 page 63" href="http://viewer.zmags.com/publication/596c0327?page=63"> was similar to that seen in the overall p</a> <a title="EMJ Hematology 4.1 2016 page 64" href="http://viewer.zmags.com/publication/596c0327?page=64"> Annual Meeting, 9-12 June 2016. 34. San-Miguel </a> <a title="EMJ Hematology 4.1 2016 page 65" href="http://viewer.zmags.com/publication/596c0327?page=65"> Phase 2 Study of the All-Oral Combination of Inv</a> <a title="EMJ Hematology 4.1 2016 page 66" href="http://viewer.zmags.com/publication/596c0327?page=66"> Abstract Reviews EVIDENCE-BASED TRANSFUSION MEDIC</a> <a title="EMJ Hematology 4.1 2016 page 67" href="http://viewer.zmags.com/publication/596c0327?page=67"> EHA 2016 in a given patient for a given procedur</a> <a title="EMJ Hematology 4.1 2016 page 68" href="http://viewer.zmags.com/publication/596c0327?page=68"> Abstract Reviews with lower limb SVT not involvi</a> <a title="EMJ Hematology 4.1 2016 page 69" href="http://viewer.zmags.com/publication/596c0327?page=69"> EHA 2016 GBT440 treatment compared with </a> <a title="EMJ Hematology 4.1 2016 page 70" href="http://viewer.zmags.com/publication/596c0327?page=70"> Abstract Reviews (mutant JAK2, MPL or CALR, or t</a> <a title="EMJ Hematology 4.1 2016 page 71" href="http://viewer.zmags.com/publication/596c0327?page=71"> EHA 2016 FAMILY-DIRECTED CORD BLOOD BANKIN</a> <a title="EMJ Hematology 4.1 2016 page 72" href="http://viewer.zmags.com/publication/596c0327?page=72"> Abstract Reviews RESULTS A total of 338 directed</a> <a title="EMJ Hematology 4.1 2016 page 73" href="http://viewer.zmags.com/publication/596c0327?page=73"> EHA 2016 conservative approximation of progre</a> <a title="EMJ Hematology 4.1 2016 page 74" href="http://viewer.zmags.com/publication/596c0327?page=74"> Abstract Reviews function, whilst others h</a> <a title="EMJ Hematology 4.1 2016 page 75" href="http://viewer.zmags.com/publication/596c0327?page=75"> EHA 2016 CHRONIC LYMHOCYTIC LEUKAEMIA: TREATMEN</a> <a title="EMJ Hematology 4.1 2016 page 76" href="http://viewer.zmags.com/publication/596c0327?page=76"> Abstract Reviews 370(12):1101-10. 9. Hillmen P</a> <a title="EMJ Hematology 4.1 2016 page 77" href="http://viewer.zmags.com/publication/596c0327?page=77"> EMJ EUROPEAN MEDICAL </a> <a title="EMJ Hematology 4.1 2016 page 78" href="http://viewer.zmags.com/publication/596c0327?page=78"> EDITOR’S PICK Dire</a> <a title="EMJ Hematology 4.1 2016 page 79" href="http://viewer.zmags.com/publication/596c0327?page=79"> INTRODUCTION Bleeding events have been r</a> <a title="EMJ Hematology 4.1 2016 page 80" href="http://viewer.zmags.com/publication/596c0327?page=80"> Bioavailability If DE capsules are opened, t</a> <a title="EMJ Hematology 4.1 2016 page 81" href="http://viewer.zmags.com/publication/596c0327?page=81"> Table 1 continued. Dabigatran Rivaroxaban </a> <a title="EMJ Hematology 4.1 2016 page 82" href="http://viewer.zmags.com/publication/596c0327?page=82"> Table 1 continued. PE: pulmonary embolism; THR: </a> <a title="EMJ Hematology 4.1 2016 page 83" href="http://viewer.zmags.com/publication/596c0327?page=83"> any other anticoagulant is strictly contraindicat</a> <a title="EMJ Hematology 4.1 2016 page 84" href="http://viewer.zmags.com/publication/596c0327?page=84"> Table 2 continued. Dabigatran P-gp substrate </a> <a title="EMJ Hematology 4.1 2016 page 85" href="http://viewer.zmags.com/publication/596c0327?page=85"> Table 2 continued. Dabigatran P-gp substrate </a> <a title="EMJ Hematology 4.1 2016 page 86" href="http://viewer.zmags.com/publication/596c0327?page=86"> http:/www.fda.gov) clearly suggest an association</a> <a title="EMJ Hematology 4.1 2016 page 87" href="http://viewer.zmags.com/publication/596c0327?page=87"> Table 3 continued. Indication Emergent situation†</a> <a title="EMJ Hematology 4.1 2016 page 88" href="http://viewer.zmags.com/publication/596c0327?page=88"> with LMWH or UFH, especially for patients with hi</a> <a title="EMJ Hematology 4.1 2016 page 89" href="http://viewer.zmags.com/publication/596c0327?page=89"> Intern Med. 2015;175(1):18-24. 9. Russo V et al. </a> <a title="EMJ Hematology 4.1 2016 page 90" href="http://viewer.zmags.com/publication/596c0327?page=90"> (Randomized Evaluation of Long-Term Anticoagul</a> <a title="EMJ Hematology 4.1 2016 page 91" href="http://viewer.zmags.com/publication/596c0327?page=91"> BRIDGING TO TRANSPLANT IN DIFFUSE LA</a> <a title="EMJ Hematology 4.1 2016 page 92" href="http://viewer.zmags.com/publication/596c0327?page=92"> option is to initiate high-dose therapy pri</a> <a title="EMJ Hematology 4.1 2016 page 93" href="http://viewer.zmags.com/publication/596c0327?page=93"> 1.0 0.8 0.6 0.4 Survival probability 0.2 0.</a> <a title="EMJ Hematology 4.1 2016 page 94" href="http://viewer.zmags.com/publication/596c0327?page=94"> in patients with refractory DLBCL repor</a> <a title="EMJ Hematology 4.1 2016 page 95" href="http://viewer.zmags.com/publication/596c0327?page=95"> Table 1: Overall survival according to prognostic</a> <a title="EMJ Hematology 4.1 2016 page 96" href="http://viewer.zmags.com/publication/596c0327?page=96"> Table 2: Response rates until the end of study in</a> <a title="EMJ Hematology 4.1 2016 page 97" href="http://viewer.zmags.com/publication/596c0327?page=97"> p=0.005; HR: 0.6 [95% CI: 0.42–0.86]). Simi</a> <a title="EMJ Hematology 4.1 2016 page 98" href="http://viewer.zmags.com/publication/596c0327?page=98"> REFERENCES 1. International Agency for Research </a> <a title="EMJ Hematology 4.1 2016 page 99" href="http://viewer.zmags.com/publication/596c0327?page=99"> after high-dose therapy and autologous transplant</a> <a title="EMJ Hematology 4.1 2016 page 100" href="http://viewer.zmags.com/publication/596c0327?page=100"> THROMBOCYTOPENIA CAUSED BY INHERITED HA</a> <a title="EMJ Hematology 4.1 2016 page 101" href="http://viewer.zmags.com/publication/596c0327?page=101"> a platform for the discovery of new genetic defec</a> <a title="EMJ Hematology 4.1 2016 page 102" href="http://viewer.zmags.com/publication/596c0327?page=102"> Runt-Related Transcription Factor 1 The core bind</a> <a title="EMJ Hematology 4.1 2016 page 103" href="http://viewer.zmags.com/publication/596c0327?page=103"> Gene references Platelet disorder OMIM entry</a> <a title="EMJ Hematology 4.1 2016 page 104" href="http://viewer.zmags.com/publication/596c0327?page=104"> counts have been documented in a number of family</a> <a title="EMJ Hematology 4.1 2016 page 105" href="http://viewer.zmags.com/publication/596c0327?page=105"> caused by mutations affecting the DNA binding fac</a> <a title="EMJ Hematology 4.1 2016 page 106" href="http://viewer.zmags.com/publication/596c0327?page=106"> of defective secretion of dense granules on</a> <a title="EMJ Hematology 4.1 2016 page 107" href="http://viewer.zmags.com/publication/596c0327?page=107"> Ecotropic Viral Integration Site 1 The MECOM ge</a> <a title="EMJ Hematology 4.1 2016 page 108" href="http://viewer.zmags.com/publication/596c0327?page=108"> develop myeloid malignancies to human chromosome </a> <a title="EMJ Hematology 4.1 2016 page 109" href="http://viewer.zmags.com/publication/596c0327?page=109"> ANKRD26 regulatory region induce MAPK hype</a> <a title="EMJ Hematology 4.1 2016 page 110" href="http://viewer.zmags.com/publication/596c0327?page=110"> THE RELATIVE CONTRIBUTIONS OF GERMLINE VARI</a> <a title="EMJ Hematology 4.1 2016 page 111" href="http://viewer.zmags.com/publication/596c0327?page=111"> in leukaemia. The inability to account for paedia</a> <a title="EMJ Hematology 4.1 2016 page 112" href="http://viewer.zmags.com/publication/596c0327?page=112"> abundant somatic mutation. Well known instability</a> <a title="EMJ Hematology 4.1 2016 page 113" href="http://viewer.zmags.com/publication/596c0327?page=113"> Genome-wide association studies have identified he</a> <a title="EMJ Hematology 4.1 2016 page 114" href="http://viewer.zmags.com/publication/596c0327?page=114"> the largest absolute number of variants were in t</a> <a title="EMJ Hematology 4.1 2016 page 115" href="http://viewer.zmags.com/publication/596c0327?page=115"> paediatric cancer. While targeting developmental </a> <a title="EMJ Hematology 4.1 2016 page 116" href="http://viewer.zmags.com/publication/596c0327?page=116"> pediatric and hematologic cancers: a moving t</a> <a title="EMJ Hematology 4.1 2016 page 117" href="http://viewer.zmags.com/publication/596c0327?page=117"> CURRENT MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC </a> <a title="EMJ Hematology 4.1 2016 page 118" href="http://viewer.zmags.com/publication/596c0327?page=118"> molecular targets and newly developed therapies, </a> <a title="EMJ Hematology 4.1 2016 page 119" href="http://viewer.zmags.com/publication/596c0327?page=119"> Minimal Residual Disease MRD is the detection </a> <a title="EMJ Hematology 4.1 2016 page 120" href="http://viewer.zmags.com/publication/596c0327?page=120"> Results appeared significantly better when</a> <a title="EMJ Hematology 4.1 2016 page 121" href="http://viewer.zmags.com/publication/596c0327?page=121"> negativity was reached in 50–83% of cases and a </a> <a title="EMJ Hematology 4.1 2016 page 122" href="http://viewer.zmags.com/publication/596c0327?page=122"> a nutrient sensor and regulator of translation in</a> <a title="EMJ Hematology 4.1 2016 page 123" href="http://viewer.zmags.com/publication/596c0327?page=123"> not benefit sufficiently from imatinib, and in who</a> <a title="EMJ Hematology 4.1 2016 page 124" href="http://viewer.zmags.com/publication/596c0327?page=124"> ‘acute myeloid leukaemia-like’ chemother</a> <a title="EMJ Hematology 4.1 2016 page 125" href="http://viewer.zmags.com/publication/596c0327?page=125"> without allogeneic SCT. Furthermore, it has been </a> <a title="EMJ Hematology 4.1 2016 page 126" href="http://viewer.zmags.com/publication/596c0327?page=126"> 20. Mohty M et al. Reduced intensity conditioning</a> <a title="EMJ Hematology 4.1 2016 page 127" href="http://viewer.zmags.com/publication/596c0327?page=127"> complete remissions in adults with relaps</a> <a title="EMJ Hematology 4.1 2016 page 128" href="http://viewer.zmags.com/publication/596c0327?page=128"> like acute lymphoblastic leukemia. Blood. 2012;12</a> <a title="EMJ Hematology 4.1 2016 page 129" href="http://viewer.zmags.com/publication/596c0327?page=129"> MANAGEMENT OF CHILDREN WITH SICKLE CELL DISEASE I</a> <a title="EMJ Hematology 4.1 2016 page 130" href="http://viewer.zmags.com/publication/596c0327?page=130"> Europe and identifying the greatest unmet clinica</a> <a title="EMJ Hematology 4.1 2016 page 131" href="http://viewer.zmags.com/publication/596c0327?page=131"> MANAGEMENT OF SICKLE CELL DISEASE IN CHILDHOOD AN</a> <a title="EMJ Hematology 4.1 2016 page 132" href="http://viewer.zmags.com/publication/596c0327?page=132"> SCD, not only in research studies but also</a> <a title="EMJ Hematology 4.1 2016 page 133" href="http://viewer.zmags.com/publication/596c0327?page=133"> Currently, a study is underway to determine the l</a> <a title="EMJ Hematology 4.1 2016 page 134" href="http://viewer.zmags.com/publication/596c0327?page=134"> in the 21st century: incidence, diagnosis and hee</a> <a title="EMJ Hematology 4.1 2016 page 135" href="http://viewer.zmags.com/publication/596c0327?page=135"> insufficiency. Ann Hematol. 2004;83(1): 18-21. 51</a> <a title="EMJ Hematology 4.1 2016 page 136" href="http://viewer.zmags.com/publication/596c0327?page=136"> UPCOMING EVENTS 18th Meeting of the European Asso</a> <a title="EMJ Hematology 4.1 2016 page 137" href="http://viewer.zmags.com/publication/596c0327?page=137"> HEMATOLOGY 10th Anniversary Conference Academy fo</a> <a title="EMJ Hematology 4.1 2016 page 138" href="http://viewer.zmags.com/publication/596c0327?page=138"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Hematology 4.1 2016 page 139" href="http://viewer.zmags.com/publication/596c0327?page=139"> Buyer’s Guide • ABBVIE • ADAPTIVE BIOTECHNOL</a> <a title="EMJ Hematology 4.1 2016 page 140" href="http://viewer.zmags.com/publication/596c0327?page=140"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>